Cite
HARVARD Citation
Nauck, M. et al. (n.d.). Taspoglutide, a once‐weekly glucagon‐like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open‐label randomized trial. Diabetic medicine. 30 (1), pp. 109-113. [Online].